Investor Area

News

Announcements by type

  • Presentation

  • Corporate

  • Newsletter

  • Regulatory

  • Financial

  • Clinical

  • Reset

 

  CLINUVEL PHARMACEUTICALS LTD today announced that it has renewed the Employment Agreement with life science executive and CLINUVEL Managing Director Dr Philippe Wolgen for a term of three years ending 1 July 2022. […] Download PDF

Download PDF
 
 
Wednesday, 02 October 2019

FDA Clarifies SCENESSE® PDUFA Date

  CLINUVEL PHARMACEUTICALS LTD today announced that the US Food and Drug Administration (FDA) has notified the company that the Prescription Drug User Fee Act (PDUFA) goal date for review of the submission of the SCENESSE® (afamelanotide 16mg) scientific dossier had been miscommunicated by the Agency and now has been confirmed for 8 October 2019, […]

Download PDF
 
 
Monday, 30 September 2019

CLINUVEL Confirms AGM Date

  CLINUVEL PHARMACEUTICALS LTD today announced it will hold its 2019 Annual General Meeting of shareholders on Wednesday 20 November 2019 at 10.00 am AEDT. […] Download PDF

Download PDF
 
 
Wednesday, 25 September 2019

Appendix 3X

  Initial Director’s Interest Notice Download PDF

Download PDF
 
 
Monday, 23 September 2019

CLINUVEL Appoints New Director

  CLINUVEL PHARMACEUTICALS LTD today announced the appointment of Susan (Sue) Smith as a Non-Executive Director of the Group’s Board of Directors. The appointment is effective today. […] Download PDF

Download PDF
 
 
Tuesday, 10 September 2019

SCENESSE® presented at ICPP in Milan

  CLINUVEL PHARMACEUTICALS LTD today announced that safety and effectiveness data from the treatment of erythropoietic protoporphyria (EPP) patients with SCENESSE® (afamelanotide 16mg), will be presented this week at the International Congress on Porphyrins and Porphyrias (ICPP) in Milan, Italy. […] Download PDF

Download PDF
 
 
Tuesday, 03 September 2019

Appendix 3Y

  Change of Director’s Interest Notice Appendix 3Y    

Download PDF
 
 

  Download Notification of Dividend/Distribution

Download PDF
 
 
Wednesday, 28 August 2019

CLINUVEL Clarifies ex-Dividend Date

  In relation to the dividend announcement earlier today, CLINUVEL PHARMACEUTICALS LTD clarifies the ex-dividend date is to be 04 September 2019. Download PDF

Download PDF
 
 
Wednesday, 28 August 2019

CLINUVEL Declares Final Dividend

  CLINUVEL PHARMACEUTICALS LTD is pleased to announce that it will issue a dividend for the financial year ended 30 June 2019. This is the second final dividend in its corporate history. […] Download PDF

Download PDF
 
 

  CLINUVEL PHARMACEUTICALS LTD (CLINUVEL), a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4E and Preliminary Financial Report for the year ending 30 June 2019. […] Download PDF

Download PDF
 
 

  CLINUVEL PHARMACEUTICALS LTD today announced that its program in systemic photoprotection will be discussed and presented at the first European-American meeting of the International Congress on Photobiology and Congress of the European Society for Photobiology, Light and Life, held in Barcelona, Spain, from 25-30 August. […] Download PDF

Download PDF
 
 
Tuesday, 20 August 2019

CLINUVEL Newsletter – August 2019

  Dear patients, shareholders, friends, In this News Communiqué VI for the year we report further on CLINUVEL’s regulatory progress in the US and the latest quarterly results for the period ending 30 June 2019. […] Download PDF

Download PDF
 
 
Wednesday, 31 July 2019

Appendix 4C

  CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4C – Quarterly Cashflow Report for the period 01 April to 30 June 2019.   Download PDF

Download PDF
 
 

  CLINUVEL PHARMACEUTICALS LTD today announced that non-executive Director, Willem Blijdorp has replaced Managing Director and Chief Executive Officer, Dr Philippe Wolgen as a member of the Audit & Risk Committee. […] Download PDF

Download PDF
 
Thursday, 23 July 2020

Kommuniqué IV

Liebe Aktionäre, Freunde,Es stellt sich eine neue Welt dar, die darauf hinweist, dass das Virus nicht so leicht zu beseitigen sein wird. Waehrend wir es akzeptieren, einen Modus der Koexistenz zu finden, muessen wir für …

Download PDF
 
Wednesday, 22 July 2020

CLINUVEL Newsletter

Communiqué IV, 2020 – 22 July 2020 Dear shareholders, friends,As a new world presents itself indicating that the virus will not easily be eliminated as we are accepting to find a modus co-existentiae, albeit we …

Download PDF
 
Thursday, 21 May 2020

Kommuniqué III

Liebe Aktionäre, Freunde,Die außergewöhnlichen Zeiten, in denen wir leben, haben alle Kontinente beeinflusst. Jedes verlorene Leben war eins zu viel. Ich kann unseren italienischen medizinischen Kollegen, Patienten und Familien, die mit der Tragödie kämpfen, nicht …

Download PDF
 
Tuesday, 19 May 2020

CLINUVEL Newsletter

Dear shareholders, friends,The extraordinary times in which we are living have affected all continents. Each life lost has been one too many. I cannot express enough empathy to our Italian medical colleagues, patients and families …

Download PDF
 
Friday, 08 May 2020

Chair Letter to Shareholders

Fellow shareholders,In my March letter I wished all good health during uncertain times. It is now clear the extent of damage COVID-19 has caused and will cause for many years in the future. I want …

Download PDF
 

Innovative drug launched for rare, isolating, “light intolerance” disorder Americans living with a rare genetic disorder that forces them to choose between self-isolation in the dark, or burning reactions from exposure to light, are welcoming an …

www.clinuvel.com

 

1 SCENESSE® (afamelanotide 16mg) is approved in the European Union as an orphan medicinal product for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). SCENESSE® is approved in the USA to increase pain free light exposure in adult EPP patients with a history of phototoxicity. Information on the product, including the approved prescribing information, can be found on CLINUVEL’s website at www.clinuvel.com.

2 Biolcati et al. (2015). Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. The British Journal of Dermatology. 172(6), 1601–1612. Langendonk et al. (2015). Afamelanotide for Erythropoietic Protoporphyria. The New England Journal of Medicine. 373(1), 48–59. Wensink et al. (2020). Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice. JAMA Dermatology. EPub 18 March 2020.

Download PDF

 

CLINUVEL PHARMACEUTICALS LTD today announced that US insurance companies have agreed to reimburse SCENESSE® (afamelanotide) for patients diagnosed with erythropoietic protoporphyria (EPP).1SCENESSE® was approved by the US Food and Drug Administration (FDA) in October 2019 …

www.clinuvel.com.

2 Further details and terms and conditions are available from www.scenesse.com. This site is intended for US residents only.

Download PDF

 
Monday, 23 March 2020

CLINUVEL Kommuniqué II

Sehr geehrte Aktionäre, liebe Freunde,im Laufe des Jahres haben wir einen deutlichen Rückgang der globalen Aktienmärkte erlebt, der den Wertverlust von CLINUVEL noch verstärkt hat. Obwohl dies für viele unserer Aktionäre, einschließlich der Mitarbeiter, die …

Download PDF
 
Thursday, 19 March 2020

CLINUVEL Newsletter

Dear shareholders, friends,As the year unfolds, we have witnessed the significant downturn of global stock markets which has compounded the decline of CLINUVEL’s value. While regretful and painful for many of our shareholders, including staff …

Download PDF
 
Thursday, 12 March 2020

Chair Letter to Shareholders

Fellow shareholders,Let me start a first welcome letter by wishing you a successful and great year ahead without health issues, pertinent at the time that Corona virus is taking over the world news.Since appointed in …

Download PDF